News

Discovery Assay Development of Biomarkers Predictive of Preterm Birth

Sera Prognostics, Inc. presented the development and analytical performance of a highly multiplexed and targeted mass spectrometry-based assay for biomarker discovery and subsequent clinical diagnostic development. Using this advanced MRM method, biomarkers were identified across multiple pathways of relevance to preterm birth.

American Society of Mass Spectrometry Presentation

Source

June 2014

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184